LON:ERGO Ergomed (ERGO) Share Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free ERGO Stock Alerts GBX 1,346 0.00 (0.00%) (As of 11/13/2023) Add Compare Share Share Today's Range 1,346▼ 1,34650-Day Range 1,346▼ 1,34652-Week Range 895▼ 1,380Volume280,999 shsAverage Volume346,578 shsMarket Capitalization£701.00 millionP/E Ratio4,641.38Dividend YieldN/APrice TargetGBX 1,400 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartHeadlinesInsider Trades Get Ergomed alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Ergomed Stock (LON:ERGO)Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.Read More ERGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERGO Stock News HeadlinesFebruary 6, 2024 | morningstar.comIcon PLC IJFJanuary 14, 2024 | finanznachrichten.deGreen Mining Innovation: Neuer Chief Financing OfficerMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.January 13, 2024 | finanznachrichten.deGreen Mining Innovation: New Chief Financing OfficerJanuary 4, 2024 | msn.comPermira Hires Maschmeyer From Vistria for Health-Care InvestingDecember 31, 2023 | msn.com3 high-growth penny stocks to consider buying for 2024November 14, 2023 | finance.yahoo.comErgomed strongly positioned for future growth in new partnership with PermiraOctober 19, 2023 | uk.finance.yahoo.comInvesco Ltd: Form 8.3 - Ergomed PLCMarch 28, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.October 10, 2023 | msn.comWakefield-based fds advises on sale of an Isle of Man pharmaceutical company to global firm Ergomed PLCOctober 2, 2023 | uk.finance.yahoo.comMan Group PLC : Form 8.3 - Ergomed plcSeptember 22, 2023 | marketwatch.comErgomed Expects to Meet Full-Year Views After Pretax Profit Edged UpSeptember 18, 2023 | finance.yahoo.comForm 8.3 - Ergomed_PLCSeptember 12, 2023 | finanznachrichten.deSamson Rock Capital LLP - Form 8.3 - Ergomed PlcSeptember 7, 2023 | finance.yahoo.comForm 8.3 - ERGO LNSeptember 5, 2023 | msn.comPrivate equity swoops on UK pharma firm in £703.1m deal: Ergomed founder lands £120m windfallSeptember 5, 2023 | msn.comLife science founder net worth tops £120m after private equity swoopSeptember 4, 2023 | msn.comPrivate equity swoops on UK pharma firm Ergomed in £703.1m dealSeptember 4, 2023 | thetimes.co.ukUK’s Ergomed agrees £703m takeover by private equity firm PermiraSeptember 4, 2023 | markets.businessinsider.comErgomed Share Price Surges Over 14% on Takeover AnnouncementSeptember 4, 2023 | ft.comErgomed/Permira: buyout group sees drug trial group as contract thrillerSeptember 4, 2023 | uk.finance.yahoo.comForm 8.3 - Octopus Investments - Ergomed plcSeptember 4, 2023 | msn.comBidco to acquire biopharmaceutical services company ErgomedSeptember 4, 2023 | msn.comSignal: UK clinical trials provider Ergomed bought out in $888m dealSeptember 4, 2023 | yahoo.comFTSE 100 Live: Asia shares lift, blue-chips seen higherSeptember 4, 2023 | msn.comPrivate equity firm Permira to buy UK's Ergomed for 703 million poundsSeptember 4, 2023 | reuters.comUK's Ergomed agrees for 703 million pound buyout deal with PermiraSee More Headlines Receive ERGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/18/2017Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ERGO CUSIPN/A CIKN/A Webwww.ergomedplc.com Phone+44-1483-503205FaxN/AEmployees1,400Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,400 High Stock Price TargetGBX 1,450 Low Stock Price TargetGBX 1,350 Potential Upside/Downside+4.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.29 Trailing P/E Ratio4,641.38 Forward P/E Ratio26.11 P/E GrowthN/ANet Income£15 million Net Margins9.87% Pretax MarginN/A Return on Equity18.08% Return on Assets10.16% Debt Debt-to-Equity Ratio3.32 Current Ratio1.79 Quick Ratio1.22 Sales & Book Value Annual Sales£152.09 million Price / Sales4.61 Cash FlowGBX 24.62 per share Price / Cash Flow54.67 Book ValueGBX 179 per share Price / Book7.52Miscellaneous Outstanding Shares52,080,000Free FloatN/AMarket Cap£701.00 million OptionableNot Optionable Beta0.79 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Miroslav Reljanovic (Age 64)Founder & Executive Chairman Comp: $964.3kMr. Michael William Spiteri (Age 62)Chief Transformation & Technology Officer Comp: $52.77kJonathan Andrew Curtain (Age 47)CFO & Executive Director Dr. Michael ForstnerHead of Risk Management & PharmacoepidemiologyMs. Sally AmanuelPresident of PrimeVigilanceDr. Gordana TonkovicPresident of Clinical ResearchMs. Ronel SteynSenior Vice President of Global DevelopmentKeith ByrneSenior Vice-President of Capital Markets & StrategyJoanne BletcherCompany SecretaryMore ExecutivesKey CompetitorsPureTech HealthLON:PRTCSilence TherapeuticsLON:SLNOxford Nanopore TechnologiesLON:ONTHorizon Discovery Group plc (HZD.L)LON:HZDBioventixLON:BVXPView All Competitors ERGO Stock Analysis - Frequently Asked Questions Should I buy or sell Ergomed stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ergomed in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ERGO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERGO, but not buy additional shares or sell existing shares. View ERGO analyst ratings or view top-rated stocks. What is Ergomed's stock price target for 2024? 3 brokerages have issued 12 month target prices for Ergomed's stock. Their ERGO share price targets range from GBX 1,350 to GBX 1,450. On average, they expect the company's share price to reach GBX 1,400 in the next year. This suggests a possible upside of 4.0% from the stock's current price. View analysts price targets for ERGO or view top-rated stocks among Wall Street analysts. How have ERGO shares performed in 2024? Ergomed's stock was trading at GBX 1,346 on January 1st, 2024. Since then, ERGO stock has increased by 0.0% and is now trading at GBX 1,346. View the best growth stocks for 2024 here. How were Ergomed's earnings last quarter? Ergomed plc (LON:ERGO) released its quarterly earnings results on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The firm had revenue of $22.91 million for the quarter. Ergomed had a net margin of 9.87% and a trailing twelve-month return on equity of 18.08%. What other stocks do shareholders of Ergomed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), Axsome Therapeutics (AXSM), FuelCell Energy (FCEL), NIO (NIO), Science Applications International (SAIC), Northern Dynasty Minerals (NAK), Tilray (TLRY), Agilent Technologies (A) and American Express (AXP). How do I buy shares of Ergomed? Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ERGO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ergomed plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.